MONTREAL, April 26, 2013 /PRNewswire-iReach/ --Micropharma Limited, a pioneer in the development of innovative and effective products based on the human microbiome, today announced that after three years of development it has a timeline for launch of its ingestible gastrointestinal sampling technology.
Manipulation of the gut microbiome is becoming an important way to treat immune, gastrointestinal and metabolic disease. Probiotic therapies affecting the human gut microbiome have gained regulatory approval and are now included as part of clinical guidelines for a wide range of indications. Further, there are now a number of microbiome focused companies actively developing microbiome based diagnostics, identifying uses for small molecules acting through the microbiome and developing GMO stains to affect the microbiome.
Via Clara Belzer